Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

VVOS vs ABVC: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ABVC Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 8–0 Matrix Metrics)

ABVC Overall Winner 6-Pillar Tally: VVOS 2 – 3 ABVC (1 Tie) Matrix Metrics: VVOS 0 – 8 ABVC

As of Nov 20, 2026, ABVC BioPharma, Inc. (ABVC) is the stronger overall head-to-head candidate over Vivos Therapeutics, Inc. (VVOS) in the Tradestie Institutional Equity Comparison Engine, winning 8–0 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). VVOS carries a Unified Composite Score of 36.4/100 (SELL) at $0.05 (N/M Forward P/E, -107.9% operating margin), whereas ABVC carries 47.4/100 (HOLD) at $0.87 (N/M Forward P/E, 0.0% operating margin).

  • Technical & Structure Timing Caution: VVOS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 18.9); meanwhile ABVC trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 35.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About VVOS vs ABVC
VVOS NASDAQ
Vivos Therapeutics, Inc. Common Stock
Surgical & Medical Instruments & Apparatus
$0.05
-5.1% 1D
Market Cap $1.9M
TTM Revenue $21M
Forward P/E N/M
Beta / 30D Vol 1.70β · 111% Vol
Unified Composite Score
36.4 / 100 SELL
Tech 25.0 Fund 35.0 Flow 50.0 Mom 30.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -29.8%), weak momentum, RSI 19
RSI-14: 18.9 · SMA20: $0.10 · SMA50: $0.13
ABVC NASDAQ Head-to-Head Winner
ABVC BioPharma, Inc. Common Stock
Pharmaceutical Preparations
$0.87
-1.56% 1D
Market Cap $23.9M
TTM Revenue $797,916
Forward P/E N/M
Beta / 30D Vol 1.24β · 44% Vol
Unified Composite Score
47.4 / 100 HOLD
Tech 43.0 Fund 50.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 35
RSI-14: 35.2 · SMA20: $0.98 · SMA50: $1.01

6-Pillar Scorecard Institutional Category Breakdown (VVOS 2 – 3 ABVC)

Columns: Metric · VVOS · ABVC
1. Valuation Multiples VVOS
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 0.1x 29.9x
2. Growth & Scale ABVC
Revenue Growth (YoY) +34.9% +104.5%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $21M $797,916
Market Cap $1.9M $23.9M
3. Profitability & Quality ABVC
Gross Margin 61.9% 100.0%
Operating Margin -107.9% 0.0%
Net Profit Margin -121.8% 0.0%
Return on Equity (ROE) -8585.3% -52.7%
4. Balance Sheet & Cash Flow VVOS
Cash Generation (TTM) -$21M EBITDA -$5.8M EBITDA
Cash Flow Margin -99.3% EBITDA Mgn N/A
Net Cash / Leverage -8585.3% ROE $0.50 Book/Sh · -52.7% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ABVC
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: VVOS (0) vs ABVC (8)
Institutional Metric VVOS ABVC Criterion Row Edge
Market Capitalization
Scale
$1.9M $23.9M Larger Scale ABVC
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+34.9% +104.5% Higher Growth ABVC
Operating Margin (TTM)
Profitability
-107.9% 0.0% Higher Margin ABVC
Net Profit Margin
Profitability
-121.8% 0.0% Higher Margin ABVC
Return on Equity (ROE)
Capital Efficiency
-8585.3% -52.7% Higher ROE ABVC
52-Week Range Position
Momentum
0% ($0–$3) 7% ($1–$3) Stronger Trend ABVC
Beta / 30D Volatility
Risk Regime
1.70β · 111% Vol 1.24β · 44% Vol Lower Realized Risk ABVC
Unified Institutional Score
Composite Signal
36.4 / 100 (SELL) 47.4 / 100 (HOLD) Higher Composite ABVC
Trailing 12M Revenue (USD)
Operating Scale
$21M $797,916 FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
61.9% 100.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 0.1x EV/Rev N/M PEG · 29.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$21M EBITDA (-8585.3% ROE) -$5.8M EBITDA ($0.50 Book/Sh · -52.7% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ABVC +41.97 pp
VVOS: -59.25% · ABVC: -17.28%
3M Horizon ABVC +83.62 pp
VVOS: -80.49% · ABVC: +3.13%
6M Horizon ABVC +67.14 pp
VVOS: -91.15% · ABVC: -24.01%
1Y Horizon ABVC +29.56 pp
VVOS: -97.71% · ABVC: -68.15%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on VVOS vs ABVC. Trailing 12-month operating profitability (VVOS -107.9% vs ABVC 0.0%) and valuation multiples (VVOS N/M vs ABVC N/M Forward P/E) are benchmarked directly in Pillar 4 below.

VVOS ADR TTM Benchmark FX-Normalized USD
TTM Revenue$21M
Gross Margin61.9%
Op. Margin-107.9%
ROE / Fwd P/E-8585.3% · N/M
ABVC ADR TTM Benchmark FX-Normalized USD
TTM Revenue$797,916
Gross Margin100.0%
Op. Margin0.0%
ROE / Fwd P/E-52.7% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
VVOS BREAKDOWN
113d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact VVOS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ABVC UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ABVC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
VVOS Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $1.9M market capitalization and -107.9% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ABVC Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $23.9M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ VVOS vs ABVC Key Questions & Quantitative Answers

As of Nov 20, 2026, ABVC BioPharma, Inc. (ABVC) is the stronger overall head-to-head candidate over Vivos Therapeutics, Inc. (VVOS) in the Tradestie Institutional Equity Comparison Engine, winning 8–0 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). VVOS carries a Unified Composite Score of 36.4/100 (SELL) at $0.05 (N/M Forward P/E, -107.9% operating margin), whereas ABVC carries 47.4/100 (HOLD) at $0.87 (N/M Forward P/E, 0.0% operating margin). Technical & Structure Timing Caution: VVOS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 18.9); meanwhile ABVC trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 35.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ABVC leads the Growth & Scale pillar: VVOS posts +34.9% YoY revenue growth and +0.0% YoY earnings growth on $21M TTM revenue (61.9% gross margin, -107.9% operating margin), compared with ABVC at +104.5% YoY revenue growth and +0.0% YoY earnings growth on $797,916 TTM revenue (100.0% gross margin, 0.0% operating margin). On trailing 12-month operating scale, VVOS generates $21M in USD-normalized revenue versus $797,916 for ABVC. In operating R&D and SG&A reinvestment, VVOS deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ABVC.

VVOS screens cheaper on headline valuation multiples. VVOS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.1x EV/Revenue (-99.3% EBITDA margin), whereas ABVC trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 29.9x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against VVOS (-8585.3% ROE) versus ABVC (-52.7% ROE) capital efficiency.

In options market volatility and institutional positioning, VVOS carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.70β · 111% Vol realized risk). By comparison, ABVC carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.24β · 44% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.